2016
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer
Santarpia L, Bottai G, Kelly CM, Győrffy B, Székely B, Pusztai L. Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. The Oncologist 2016, 21: 1063-1078. PMID: 27384237, PMCID: PMC5016060, DOI: 10.1634/theoncologist.2015-0369.Peer-Reviewed Original ResearchConceptsBreast cancerCancer-causing genesCopy number variationsRNA speciesRNA editingGenomic variationNext-generation sequencingRNA sequencingGenomic complexityGenomic portraitGreater genomic complexityOncogenic mutationsOncogenic eventsTarget profilingRare mutationsMutationsRecurrent mutationsSomatic variantsGenetic aberrationsFormal clinical trialsPotential therapeutic implicationsDriver mutationsSequencingGermline variantsMolecular abnormalities
2014
TP53 mutation‐correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53‐mutated breast cancers
Győrffy B, Bottai G, Lehmann-Che J, Kéri G, Őrfi L, Iwamoto T, Desmedt C, Bianchini G, Turner NC, de Thè H, André F, Sotiriou C, Hortobagyi GN, Di Leo A, Pusztai L, Santarpia L. TP53 mutation‐correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53‐mutated breast cancers. Molecular Oncology 2014, 8: 508-519. PMID: 24462521, PMCID: PMC5528634, DOI: 10.1016/j.molonc.2013.12.018.Peer-Reviewed Original ResearchConceptsBreast cancerTP53 mutation statusPrognostic valueBC cellsMutation statusER-negative breast cancerDifferent BC cell linesFuture clinical trialsSignificant prognostic markerPotential therapeutic targetBC cell linesType of treatmentNeoadjuvant chemotherapyBC patientsClinical behaviorPrognostic markerClinical trialsConventional chemotherapyEstrogen receptorPotent small molecule inhibitorsTumor relapseSmall molecule inhibitorsTherapeutic targetClinical relevanceTP53 status
2012
Distinct tumor protein p53 mutants in breast cancer subgroups
Dumay A, Feugeas J, Wittmer E, Lehmann‐Che J, Bertheau P, Espié M, Plassa L, Cottu P, Marty M, André F, Sotiriou C, Pusztai L, de Thé H. Distinct tumor protein p53 mutants in breast cancer subgroups. International Journal Of Cancer 2012, 132: 1227-1231. PMID: 22886769, DOI: 10.1002/ijc.27767.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsDNA-Binding ProteinsFemaleHumansMutationNuclear ProteinsTumor Protein p73Tumor Suppressor Protein p53Tumor Suppressor ProteinsConceptsBasal tumorsLuminal tumorsMolecular apocrine tumoursDifferent breast cancer subtypesBreast cancer subgroupsBreast cancer subtypesP53 mutation statusApocrine tumorsTumor protein p53Molecular apocrineCancer subgroupsBreast cancerTP53 alterationsMutation statusBreast tumorsLoss of functionCancer subtypesTumorsComplex mutationsP53 gainHigh frequencyHigh rateDifferent functional consequencesMissense mutationsProtein p53
2011
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial
Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L, Moulder-Thompson S, Dewar JA, Thompson AM. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Research And Treatment 2011, 128: 783-794. PMID: 21655990, DOI: 10.1007/s10549-011-1612-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCyclic Nucleotide Phosphodiesterases, Type 3FemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansHypoglycemic AgentsInsulinKi-67 AntigenMetforminMiddle AgedReproducibility of ResultsSignal TransductionTumor Suppressor Protein p53ConceptsTumor necrosis factor receptor 1Breast cancerCore biopsyPilot cohortOperable invasive breast cancerNon-diabetic womenOperable breast cancerInvasive breast cancerPrimary breast cancerEffect of metforminNecrosis factor receptor 1Serum insulin determinationsMessenger RNA expressionAnti-proliferative effectsFactor receptor 1Ingenuity Pathway AnalysisDiabetic womenMetformin 500Neoadjuvant chemotherapyControl patientsGastrointestinal upsetMetformin armSerum insulinTherapeutic trialsMetformin treatmentDistinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers
Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de Thé H, Pusztai L. Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers. Clinical Cancer Research 2011, 17: 2591-2601. PMID: 21248301, DOI: 10.1158/1078-0432.ccr-10-1045.Peer-Reviewed Original ResearchConceptsER- cancersPredictive valueBreast cancerP53 signatureWorse distant metastasis-free survivalDistant metastasis-free survivalER-negative breast cancerAdjuvant tamoxifen therapyDifferent molecular subsetsMetastasis-free survivalDifferent prognostic valueNegative breast cancerHigher chemotherapy sensitivityTamoxifen therapyFree survivalBetter prognosisER-positivePoor prognosisPrognostic valuePrognostic markerMolecular subsetsChemotherapy sensitivityMutation statusP53 mutationsMultivariate analysis
2009
Triple-negative breast cancer—current status and future directions
Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer—current status and future directions. Annals Of Oncology 2009, 20: 1913-1927. PMID: 19901010, DOI: 10.1093/annonc/mdp492.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBasal-like breast cancerBreast cancerBreast cancer—current statusStandard cytotoxic chemotherapy regimensHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Common cytotoxic agentsCytotoxic chemotherapy regimensGrowth factor receptor 2Factor receptor 2Chemotherapy regimensClinical featuresUnfavorable prognosisProgesterone receptorLack of expressionNovel agentsReceptor 2Cytotoxic agentsPrognosisComplete concordanceCancerGene expression analysisHigh-throughput gene expression analysisRegimens